Volume 93, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Post-kala-azar dermal leishmaniasis (PKDL) is a chronic dermatosis that generally occurs after apparent cure of visceral leishmaniasis caused by . In view of the prolonged treatment regimens necessary for PKDL, noncompliance is a major limitation; an optimal regimen is yet to be defined, but 12 weeks of therapy with miltefosine is generally recommended. We performed a single-arm open-label trial of miltefosine administered daily for 16 weeks in 27 patients in Kolkata with PKDL. After 4 weeks of treatment, nine patients were lost to follow-up because of unacceptable side effects, including severe abdominal pain, nausea, and vomiting. Of the 18 remaining patients, seven completed 12 weeks of therapy and 11 completed 16 weeks of therapy. Three of the seven who received 12 weeks of therapy and none of the 11 who received 16 weeks of therapy experienced disease relapse. Our results suggest that a 16-week course of miltefosine is required for reliable cure of PKDL. Further, the study highlighted the urgent need for a multicentric randomized controlled trial of 12 versus 16 weeks of treatment with miltefosine for PKDL so as to achieve the goal of elimination of leishmaniasis in south Asia.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Ganguly S, Das NK, Barbhuiya JN, Chatterjee M, 2010. Post-kala-azar dermal leishmaniasis—an overview. Int J Dermatol 49: 921931.
    [Google Scholar]
  2. Mukhopadhyay D, Dalton JE, Kaye PM, Chatterjee M, 2014. Post kala-azar dermal leishmaniasis: an unresolved mystery. Trends Parasitol 30: 6574.
    [Google Scholar]
  3. Mishra J, Madhubala R, Singh S, 2013. Visceral and post kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern. Parasitol Res 112: 10011009.
    [Google Scholar]
  4. Sundar S, Sinha P, Jha TK, Chakravarty J, Rai M, Kumar N, Pandey K, Narain MK, Verma N, Das VN, Das P, Berman J, Arana B, 2013. Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. Trop Med Int Health 18: 96100.
    [Google Scholar]
  5. Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M, 2011. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J Infect Dis 204: 14271436.
    [Google Scholar]
  6. Das NK, Singh SK, Ghosh S, Sarkar A, Mukhopadhyay D, Roy S, Ganguly DN, Barbhuiya JN, Saha B, Chatterjee M, 2011. Case series of misdiagnosis with rK39 strip test in Indian leishmaniasis. Am J Trop Med Hyg 84: 688691.
    [Google Scholar]
  7. Srivastava A, Sweat JM, Azizan A, Vesely B, Kyle DE, 2013. Real-time PCR to quantify Leishmania donovani in hamsters. J Parasitol 99: 145150.
    [Google Scholar]
  8. Mouttaki T, Morales-Yuste M, Merino-Espinosa G, Chiheb S, Fellah H, Martin-Sanchez J, Riyad M, 2014. Molecular diagnosis of cutaneous leishmaniasis and identification of the causative Leishmania species in Morocco by using three PCR-based assays. Parasit Vectors 7: 420.
    [Google Scholar]
  9. Sundar S, Singh A, Chakravarty J, Rai M, 2015. Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. Scientific World Journal 2015: 414378.
    [Google Scholar]

Data & Media loading...

  • Received : 17 Nov 2014
  • Accepted : 02 Jun 2015
  • Published online : 07 Oct 2015
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error